Matthew H. Wilson, MD, PhD
Professor of Medicine
Division
Nephrology and Hypertension
Associate Professor of Medicine
Professional Bio
Matthew H. Wilson, MD, PhD, is a physician-scientist nephrologist and a Professor of Medicine in the Division of Nephrology and Hypertension within the Department of Medicine at Vanderbilt University Medical Center.
Dr. Wilson completed an Internal Medicine residency and a fellowship in Nephrology at Vanderbilt. He began his career at Baylor College of Medicine as an Assistant Professor focused on cell and gene therapy use of the non-viral piggyBac transposon system. He has successfully developed and implemented its use for gene transfer in vivo in animal models and to human cells including human T cells. This work has laid the foundation for clinical trials in the U.S. (NCT03288493, Poseida Therapeutics, Inc.) and around the world (ACTRN12617001579381, Australian New Zealand; UMIN000030984, Japan), and may open recently approved chimeric antigen T cell therapy for cancer to more patients worldwide.
Dr. Wilson serves on the board of directors of the American Society of Gene and Cell Therapy and is a member of the American Society of Nephrology. He has spoken at national and international academic conferences on his work in gene transfer and authored 47 manuscripts.
His laboratory had been engineering cell and gene transfer for kidney disease and its complications by translating this technology to address critical barriers of therapy in animal models of kidney disease. His recent work has led to two patent applications, one related to using T cells as vehicles for therapeutic proteins and another focused on engineering a cell therapy for kidney disease via regenerative medicine.
Dr. Wilson is a practicing internal medicine physician and nephrologist at the Nashville VA hospital.
Dr. Wilson completed an Internal Medicine residency and a fellowship in Nephrology at Vanderbilt. He began his career at Baylor College of Medicine as an Assistant Professor focused on cell and gene therapy use of the non-viral piggyBac transposon system. He has successfully developed and implemented its use for gene transfer in vivo in animal models and to human cells including human T cells. This work has laid the foundation for clinical trials in the U.S. (NCT03288493, Poseida Therapeutics, Inc.) and around the world (ACTRN12617001579381, Australian New Zealand; UMIN000030984, Japan), and may open recently approved chimeric antigen T cell therapy for cancer to more patients worldwide.
Dr. Wilson serves on the board of directors of the American Society of Gene and Cell Therapy and is a member of the American Society of Nephrology. He has spoken at national and international academic conferences on his work in gene transfer and authored 47 manuscripts.
His laboratory had been engineering cell and gene transfer for kidney disease and its complications by translating this technology to address critical barriers of therapy in animal models of kidney disease. His recent work has led to two patent applications, one related to using T cells as vehicles for therapeutic proteins and another focused on engineering a cell therapy for kidney disease via regenerative medicine.
Dr. Wilson is a practicing internal medicine physician and nephrologist at the Nashville VA hospital.
Education
MD - Vanderbilt University - 2001
PhD - Vanderbilt University - 2001
Internship - Internal Medicine - Vanderbilt University - 2002
Residency - Internal Medicine - Vanderbilt University - 2003
Fellowship - Clinical, Nephrology - Vanderbilt University - 2004
Fellowship - Research, Genetic Medicine - Vanderbilt University - 2006